Safety, tolerability, pharmacokinetics, and pharmacodynamics of single and multiple doses of aficamten in healthy Chinese participants: a randomized, double-blind, placebo-controlled, phase 1 study

Objectives: Aficamten is a selective, small-molecule allosteric inhibitor of cardiac sarcomere being developed as a chronic oral treatment for patients with symptomatic obstructive hypertrophic cardiomyopathy. This was the first-in-Chinese study aiming to investigate the safety, tolerability, pharma...

Descrición completa

Detalles Bibliográficos

Principais autores:	Xue Zhao, Hongzhong Liu, Wei Tian, Ligang Fang, Mengyang Yu, Xiaofei Wu, Aijing Liu, Ruijie Wan, Li Li, Jinghui Luo, Yuqiong Li, Bo Liu, Yu He, Xiaowen Chen, Yuan Li, Donghong Xu, Hongyun Wang, Xiaohong Han
Formato:	Artigo
Idioma:	Inglês
Publicado:	Frontiers Media S.A. 2023-08-01
Series:	Frontiers in Pharmacology
Assuntos:	aficamten Chinese participants safety pharmacokinetics pharmacodynamics
Acceso en liña:	https://www.frontiersin.org/articles/10.3389/fphar.2023.1227470/full
Tags:	Engadir etiqueta Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!